All In Biotech

Drug Trial Radar · NCT03881345

Ongoing Registry of Treatment of Venous Thromboembolism

Russian Registry of Treatment of Venous Thromboembolism

Last checked: Nov 20, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Apr 1, 2019

Primary completion

Mar 1, 2036

Study completion Mar 1, 2036

Sponsor

Lead sponsor
Medalp Private Surgery ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
First posted
Mar 19, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ongoing registration of patients with venous thromboembolism treated by means of antithrombotic therapy, thrombolisys, open surgery, endovenous desobstruction and stenting.

Conditions

  • Deep Vein Thrombosis
  • Thromboses, Venous
  • Thrombosis Embolism
  • Postthrombotic Syndrome
  • Pulmonary Embolism

Interventions

  • AnticoagulantsDrug

    anticoagulation according to the main diagnosis

  • Open surgeryProcedure

    removal of blood clots with open surgery

  • ThrombolysisProcedure

    removal of blood clots with thrombolysis

  • Venous stentingProcedure

    elimination of vein obstruction by stenting

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Veins patencyTime frame: Baseline, 3 and 12 months post-intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pirogov Russian National Research Medical University

    Moscow, Moscow, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.